A new SEC filing for Thermo Fisher Scientific Inc. (TMO) was recorded as of 1 August 2026, with no additional briefing disclosures available beyond that filing date for the current reporting period [Brief - 2026-08-01]. The filing prompted renewed examination of the company's financial and ownership data across the most recent available reporting windows.
Thermo Fisher's trailing twelve-month revenue stood at $46.34 billion as of 27 June 2026, representing year-over-year growth of approximately 10.5%. Net income on a TTM basis reached $6.98 billion, with a net margin of 15.07% and an operating margin of 17.58%. Gross margin was recorded at 24.45%. The company held $4.06 billion in cash against total debt of $45.65 billion. Earnings per share grew 9.35% year-over-year, and the trailing P/E ratio stood at 31.95 [SEC 10-Q - TMO - 2026-06-27].
Insider activity over the past 30 days reflected a net selling posture across 45 recorded transactions, with a combined net disposal value of approximately $20.86 million [SEC Form 4 - TMO - 2026-08]. This volume of insider disposals across multiple transactions within a single month represents the primary event that triggered the production of this report.
The prevailing interest rate environment shows the 10-year US Treasury yield at 4.69% and the 2-year yield at 4.25%, producing a normal yield curve configuration with a spread of 44 basis points [FRED DGS10] [FRED DGS2]. This yield curve shape reflects the broad fixed-income backdrop against which TMO's debt load of $45.65 billion and its equity valuation metrics are currently situated.